Dyadic International to ring the Nasdaq closing bell to celebrate recent listing, spotlight its technology

Dyadic International Inc (NASDAQ:DYAI) will spotlight the company’s novel C1 gene expression technology when founder and CEO Mark Emalfarb and members of the management team ring the Nasdaq closing on Monday.  

The ceremony will be broadcast live on Monday starting at 3:45 pm ET from the Nasdaq MarketSite Studio in Times Square, New York City.

Investors will be able to view the live Nasdaq closing bell ringing ceremony here or Nasdaq’s Facebook page. The bell ringing portion of the ceremony will also be broadcast on CNBC, Bloomberg TV and Fox Business News.

READ: Dyadic’s red-hot C1 gene expression technology gets biologic vaccines, drugs to market swiftly at lower cost

“Our recent Nasdaq listing has increased our visibility with investors and the public at large,” said Emalfarb. “This added visibility is expected to help us create long-term shareholder value and accelerate the adoption and use of our C1 platform technology to help make healthcare more accessible and affordable to patients.”

Dyadic stock was approved for listing on the tech-laden Nasdaq on April 17.

Founded in 1979, the Jupiter, Florida, biotechnology platform company, has sold a variety of industrial enzymes for more than two decades to the biofuel, animal nutrition, pulp and paper, food, and textile industries.

Three years ago, Dyadic sold its industrial technology business to DuPont’s industrial biosciences business for $75 million in cash.

Leveraging its C1 technology

Dyadic leverages its proprietary C1 technology — an industrially proven fungal gene expression technology — to help bring biologic vaccines, enzymes, proteins, biosimilars, and drugs to market faster and at a lower cost.

Dyadic’s breakthrough technology has been able to demonstrate expression levels of up to 1 milligram per 4 milliliter in microtiter wells. The company beleives the yields of protein expressed that C1 offers in microtiter wells may provide pharma companies with “sufficient quantities of protein” to identify promising new vaccine and drug candidates using the same host production organism from discovery through manufacturing.

“The pharma industry is beginning to recognize the potential productivity advantages of our C1 technology versus CHO, E.coli, baculovirus and yeast from the various classes and types of proteins which have been expressed from C1 to date,” Emalfarb earlier told Proactive Investors. “Our fully programmable C1 gene expression platform is robust, and flexible and has been used industrially for over two decades to produce products in some of the largest fermenters used in the biotechnology industry.”

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Story by ProactiveInvestors